OncoSil MEDICAL

Investor presentation

29 April 2022

Targeted Approach • Positive Impact



OncoSil Medical's targeted approach will deliver a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients

Executive Summary

OncoSil™ is a commercial-stage breakthrough device delivering targeted radiotherapy for pancreatic cancer

- Implanted device delivers targeted radiation to pancreatic tumour
- Breakthrough designation received in the EU/UK, US and Singapore

Experienced management and sales team in place

- Experienced management and sales team with appropriate background and experience to pursue market access and sales opportunities
- Approved for sale in 34 countries
- Sales team in Europe and the UK now have greater access to sites and staff to accelerate sales activity

Large global addressable market

- Global population of ~130k per annum
- Area of high unmet need with limited competition from what are considered effective treatments
- Market access and clinical development teams working on multiple activities to expand the addressable market

OncoSil™ Device

Overview

OncoSil™ is intended for the treatment of **locally advanced unresectable pancreatic cancer,** in combination with gemcitabine-based chemotherapy

OncoSil™ is a **single-use** brachytherapy device comprised of microparticles and a diluent

OncoSil™ is **implanted directly** into a pancreatic tumour via injection under **endoscopic ultrasound** guidance

98% of all radiation is delivered within **81** days of injection...

...causing damage to cancer cell DNA and killing malignant cancer cells

Management Team with a Depth of Experience and Expertise

Nigel Lange
Managing Director & CEO

30+ years experience in medical device industry

Served as Group COO and Interim Group CEO of Sirtex Medical

Dr Jon Bell MD
Chief Medical Officer

8+ years experience as an Interventional Radiologist and an internationally recognised expert in Interventional Oncology

David Turner
Head of Medical Affairs

40+ years experience in pharmaceutical, medical device and health technology industries

Henk Tissing
Director of Clinical Development

25+ years industry experience in oncology with pharmaceuticals and medical devices.

Clinical development roles at Sirtex Medical, BTG, A-Z & Sanofi Aventis

Olaf Michaelsen
Director AREA[1]

25+ years experience in implantable medical devices

Previous commercial roles at Sirtex Medical, Medtronic and LifeCell

Karl Pechmann
Chief Financial Officer

20+ years of finance experience having held several senior roles for listed and multi-national organisations

David James
Head, Manufacturing & Operations

25+ years of pharmaceutical manufacturing operations experience

1: Access, Reimbursement, Economics and Assessment

PanCO study demonstrated positive safety and efficacy signals

Of the many encouraging outcomes from the PanCO study[1], four are particularly important:

Established safety profile:
No evidence suggesting any additional risk from using OncoSil™

90.5% of OncoSil™ treated patients had **local disease control at 16 weeks**, which was the primary efficacy measure of the study and was statistically significant compared to the pre-set hypothesis

Although all study participants were initially unresectable, **1 in 3 patients (33%)** became **eligible for resection** after receiving OncoSil™, and nearly **1 in 4 patients (23.8%) underwent surgical resection with curative intent**

There was a **statistically significant reduction** in tumour volume for patients who received OncoSil™, with **57% of participants** having their tumour volume reduced by at **least 50%**

References: 1. Ross PJ, Wasan HS, Croagh D et al. Results of a Single-Arm Pilot Study of 32P Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma with Gemcitabine/Nab-Paclitaxel or FOLFIRINOX Chemotherapy. ESMO Open February 2022; 7 (1): 100356. https://www.esmoopen.com/article/S2059-7029(21)00318-5/fulltext

PanCO results showing compelling evidence of downstaging

OncoSil™ converted patients with unresectable locally advanced pancreatic cancer (LAPC) to surgically resectable, transforming their prognosis and substantially extending survival

Why is resection important?

Surgical resection remains the only potentially curative treatment for pancreatic cancer, but is limited to ~15% of patients

Patients with LAPC are inoperable due to the size of the tumour and its proximity to major blood vessels

Chemotherapy helps to convert ~7% with unresectable LAPC to surgical resection[1]

What did the PanCO study show?

Adding OncoSil™ to chemotherapy led to a high proportion of patients having substantial reductions in their tumour volume (range +11% to -90%), with 57% having a >50% reduction[2]

1 in 3 patients with unresectable LAPC receiving OncoSil™ plus chemotherapy became eligible for curative surgery[2]

Nearly 1 in 4 patients (23.8%) with unresectable LAPC receiving OncoSil™ plus chemotherapy underwent surgery with curative intent[2]

At the end of the PanCO Study with a follow-up of 32 months, 6 of the 10 resected patients remained alive, 5 without any evidence of disease (26.4–35.3 months from enrolment in the study)[2,3]

References: **1.** Allerdice S et al. Naïve indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy, versus standard-of-care treatment in unresectable locally advanced pancreatic cancer. Presented at the World Congress of GI Cancer, Annals of Oncology 2020: 31 (Suppl 3); Abstract P-260. **2.** Ross PJ et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/ nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open February 2022; 7 (1): 100356. **3.** Data on file. OncoSil Medical Ltd.

What we have accomplished

Experienced team in place

CE Marking obtained

Innovation Funding (NUB) approved
German funding of the OncoSil™ device

Enabled HDE pathway for bile duct cancer in US enabled
Application submitted to FDA

PanCO Study completed
and submitted to peer-reviewed journal

Breakthrough device designation achieved
in US, EU, UK, Singapore

Current market approvals

Europe (CE Mark)
United Kingdom
Switzerland
Singapore
Malaysia
Hong Kong
New Zealand
Turkey
Israel

FDA: Food and Drug Administration
HDE: Humanitarian Device Exemption
*Distal cholangiocarcinoma (DCC or bile duct cancer)

Strong team in place to lead commercial activities

All team members have extensive prior experience in specialist oncological application of radioisotopes at large medical device companies

Strong, long-standing relationships with key opinion leaders and centres of excellence within the EU and the UK

Able to leverage existing KOL relationships across all markets to include oncology, HPB surgery, gastroenterology, and nuclear medicine

Over **160** years experience

Germany
Dr. Frank Müller
Regional Head DACH
23 years

Christine Gold
Sr. Key Account Mgr.
22 years

U.K. & Ireland
Rachel Duggan
Regional Head U.K. & Ireland
15 years

Andy Ferrie
Key Account Mgr.
34 years

Italy
Cristiano D'Amico
Regional Head Italy
25 years

Belgium, Netherlands, Luxembourg
Tijs Pairoux
Regional Head BENELUX
22 years

Spain
Antonio Ponce Cuesta
Regional Head Spain
22 years

Sales and training activities to date

During the pandemic, the OncoSil™ team worked to achieve sales-readiness with key start-up activities

- Key experienced sales, marketing and training team in place – no need for any expansion of the team in the near term
- Distributors have been identified in other markets to expand the OncoSil footprint globally
- Training and certification of sites complete in 21 sites in EMEA and the UK
- 21 sites have received ethics approval for the OSPREY post marketing registry

This is where we are today

Market access and clinical development supporting sales activities

Sales team fully engaged with targeted Key Opinion Leaders to improve knowledge base of OncoSil™ technology.

- Face to face meetings now in place following COVID-19 access restrictions

Detailed health economic and market access analysis for the following:

- Seeking reimbursement in several European jurisdictions
- Working with private health insurers to agree reimbursement of the OncoSil™ device for their clients

Identifying programs for fully funded, government sponsored clinical trials including paid patient doses in the EU.

- Patient recruitment commenced in RAH clinical study
- FOLFIRINOX patient recruitment targeted for Q3 2022

Ongoing dialogue with the FDA on the following:

- Concerning approval of the HDE in dCCA to facilitate rapid entry into the US market
- Design of a pivotal study in support of a Pre-Market Approval (PMA) in LAPC

Actively pursuing new market opportunities via distributors in EU and ME.

Innovation Funding (NUB) in Germany

Funding for the use of the OncoSil™ device in Europe's largest market

In February 2022, the Institute for the Hospital Remuneration System (InEK) granted the OncoSil™ device with a "Positive Status 1" classification

Feb 2022

25 leading university hospital sites in Germany submitted requests for innovation funding (NUB) for the OncoSil™ device; all 25 were approved

Hospitals who have submitted NUB applications can now negotiate with Statutory Health Insurance providers ("Sickness Funds") for reimbursement of the OncoSil™ device for a set number of patient treatments for the upcoming year

The University of Cologne Hospital ethics committee has approved the OSPREY Registry, acting as central ethics approval for all hospital sites within Germany

G-BA Fully Funded trial in Germany

Fully-funded trial leading to public insurance reimbursement

In March 2022, the Federal Join Committee (G-BA) recommended a fully-funded trial take place in Germany

Mar 2022

Favourable results from the clinical trial will lead to the OncoSil™ device being fully-funded for patients in Germany through public insurance reimbursement

OncoSil will receive revenue payments for the provision of the OncoSil™ device used within the clinical trial

The 25 leading university sites in Germany who had submitted NUB requests will also be able to participate within the clinical trial

This is where we intend to go

Commercial Vision in 2022



Disclaimer

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction.
This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they
will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved.
In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to
obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents
or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 29 April 2022.

Nigel Lange

CEO & Managing Director

E: nigel.lange@oncosil.com

OncoSil Medical Ltd
www.oncosil.com

T: +49 30 300 149 3043

Targeted Approach • Positive Impact